NVS
NYSEHealthcareLoading…
Novartis AG Common Stock
Sector: Healthcare•United States•Market Cap: $291.4B
Related News
Latest stories connected to NVS
- RS 78Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a weekCNBC•11h ago•Original source
- RS 78Novartis Strikes $3B Oncology Deal for Breast Cancer AssetZacks Investment Research•Mar 20, 2026•Original source
- RS 78FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for AdolescentsZacks Investment Research•Mar 16, 2026•Original source
- RS 78Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativaGlobeNewsWire•Mar 13, 2026•Original source
- RS 78Argus Upgrades Novartis to Buy With $180 Price TargetFinancial Modeling Prep•Mar 11, 2026•Original source
- RS 78Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks TranscriptSeeking Alpha•Mar 6, 2026•Original source
- RS 78Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EUZacks Investment Research•Mar 3, 2026•Original source
Financials
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Revenue | 54.81B | 51.72B | 46.66B | 43.46B | 43.97B | 49.90B | 48.68B | 46.10B | 43.40B | 49.44B |
| Cost of Revenue | 13.69B | 12.83B | 12.47B | 11.58B | 11.73B | 15.12B | 14.43B | 14.51B | 13.63B | 17.52B |
| Gross Profit | 41.12B | 38.90B | 34.19B | 31.88B | 32.24B | 34.78B | 34.25B | 31.59B | 29.77B | 31.92B |
| Research and Development Expenses | 10.74B | 10.02B | 11.37B | 9.17B | 8.64B | 8.98B | 9.40B | 8.49B | 8.39B | 9.04B |
| General and Administrative Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.14B | 2.19B |
| Selling and Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.86B | 12.00B |
| Selling General and Administrative Expenses | 13.31B | 12.57B | 12.52B | 12.19B | 12.83B | 14.20B | 14.37B | 13.72B | 12.46B | 14.19B |
| Other Expenses | 0 | 1.76B | 531.00M | 2.57B | 715.00M | 1.45B | 1.40B | 980.00M | 215.00M | 417.00M |
| Operating Expenses | 24.05B | 24.35B | 24.42B | 23.93B | 22.18B | 24.63B | 25.17B | 23.19B | 21.07B | 23.65B |
| Cost and Expenses | 37.74B | 37.18B | 36.89B | 35.52B | 33.92B | 39.75B | 39.59B | 37.70B | 34.70B | 41.17B |
| Net Interest Income | -812.14M | -468.74M | -246.88M | -456.89M | -834.00M | -830.00M | -657.67M | -680.55M | -692.00M | -686.00M |
| Interest Income | 374.91M | 567.68M | 629.24M | 377.74M | 71.00M | 91.00M | 245.25M | 292.67M | 110.00M | 43.00M |
| Interest Expense | 1.19B | 1.04B | 876.12M | 834.62M | 905.00M | 921.00M | 902.93M | 973.22M | 802.00M | 729.00M |
| Depreciation and Amortization | 5.35B | 6.07B | 8.28B | 6.71B | 5.60B | 6.46B | 5.83B | 6.89B | 6.08B | 6.04B |
| EBITDA | 22.99B | 20.71B | 18.25B | 14.68B | 30.91B | 17.21B | 15.62B | 20.24B | 14.59B | 14.57B |
| EBIT | 17.63B | 14.65B | 9.98B | 7.98B | 25.32B | 10.75B | 9.79B | 15.03B | 9.85B | 8.52B |
| Non Operating Income Excluding Interest | -560.86M | -102.00M | -209.00M | -31.00M | -15.26B | -595.00M | -704.00M | -6.62B | -1.15B | -256.00M |
| Operating Income | 17.07B | 14.54B | 9.77B | 7.95B | 10.06B | 10.15B | 9.09B | 8.40B | 8.70B | 8.27B |
| Total Other Income Expenses Net | -638.25M | -904.00M | -646.00M | -769.00M | 14.47B | -274.00M | -146.00M | 5.69B | 400.00M | -451.00M |
| Income Before Tax | 16.44B | 13.64B | 9.12B | 7.18B | 24.53B | 9.88B | 8.94B | 14.10B | 9.10B | 7.82B |
| Income Tax Expense | 2.40B | 1.70B | 551.00M | 1.13B | 1.63B | 1.81B | 1.79B | 1.29B | 1.60B | 1.12B |
| Net Income From Continuing Operations | 14.04B | 11.94B | 8.57B | 6.05B | 22.91B | 8.07B | 7.15B | 12.80B | 7.50B | 6.70B |
| Net Income From Discontinued Operations | 0 | 0 | 6.28B | 906.00M | 1.11B | 0 | 0 | 0 | 0 | 0 |
| Other Adjustments To Net Income | 0 | 0 | 0 | 0 | 0 | 0 | 4.59B | -186.00M | 204.00M | 0 |
| Net Income | 14.06B | 11.94B | 8.57B | 6.05B | 22.91B | 8.07B | 7.15B | 12.61B | 7.70B | 6.70B |
| Net Income Deductions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrom Line Net Income | — | — | — | — | — | — | — | — | — | — |
| EPS | 7.25 | 5.92 | 7.15 | 3.19 | 10.71 | 3.54 | 3.12 | 5.44 | 3.28 | 2.82 |
| EPS Diluted | 7.19 | 5.87 | 7.1 | 3.17 | 10.63 | 3.52 | 3.08 | 5.38 | 3.25 | 2.8 |
| Weighted Average SHS Out | 1.94B | 2.02B | 2.08B | 2.18B | 2.24B | 2.28B | 2.29B | 2.32B | 2.35B | 2.38B |
| Weighted Average SHS Out Dil | 1.96B | 2.04B | 2.09B | 2.20B | 2.26B | 2.30B | 2.32B | 2.34B | 2.37B | 2.40B |
| Fiscal Year (FMP) | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | 2.02K |
| Gross Profit Margin | 0.75 | 0.75 | 0.73 | 0.73 | 0.73 | 0.7 | 0.7 | 0.69 | 0.69 | 0.65 |
| R&D to Revenue | 0.2 | 0.19 | 0.24 | 0.21 | 0.2 | 0.18 | 0.19 | 0.18 | 0.19 | 0.18 |
| SG&A to Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 | 0.04 |
| Interest Burden | 0.93 | 0.93 | 0.91 | 0.9 | 0.97 | 0.92 | 0.91 | 0.94 | 0.92 | 0.92 |
| EBIT Margin | 0.32 | 0.28 | 0.21 | 0.18 | 0.58 | 0.22 | 0.2 | 0.33 | 0.23 | 0.17 |
| EBITDA Margin | 0.42 | 0.4 | 0.39 | 0.34 | 0.7 | 0.34 | 0.32 | 0.44 | 0.34 | 0.29 |
| EBT per EBIT | 0.96 | 0.94 | 0.93 | 0.9 | 2.44 | 0.97 | 0.98 | 1.68 | 1.05 | 0.95 |
| Effective Tax Rate | 0.15 | 0.12 | 0.06 | 0.16 | 0.07 | 0.18 | 0.2 | 0.09 | 0.18 | 0.14 |
| Tax Burden | 0.86 | 0.88 | 1.63 | 0.97 | 0.98 | 0.82 | 1.31 | 0.89 | 0.85 | 0.86 |
| Cont. Operations Profit Margin | 0.26 | 0.23 | 0.18 | 0.14 | 0.52 | 0.16 | 0.15 | 0.28 | 0.17 | 0.14 |
| Bottom Line Profit Margin | 0.26 | 0.23 | 0.32 | 0.16 | 0.55 | 0.16 | 0.24 | 0.27 | 0.18 | 0.14 |
| Operating Cycle | 239.96 | 220.8 | 246.39 | 309.21 | 287.19 | 238.5 | 220.14 | 251.59 | 268.53 | 205.64 |
| Fwd PEG Ratio | 0.85 | -0.96 | 0.11 | -0.38 | 0.04 | 1.87 | -0.41 | 0.2 | 1.31 | -0.35 |
| Earnings Yield | 0.05 | 0.06 | 0.07 | 0.04 | 0.13 | 0.04 | 0.06 | 0.08 | 0.05 | 0.05 |
| Income Quality | 1.37 | 1.48 | 1.69 | 2.35 | 0.66 | 1.69 | 1.91 | 1.13 | 1.64 | 1.71 |